Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Humana Inc. (NYSE:HUM – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,880 shares of the insurance provider’s stock after buying an additional 1,237 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Humana were worth $21,004,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Everence Capital Management Inc. lifted its stake in shares of Humana by 4.0% during the 4th quarter. Everence Capital Management Inc. now owns 4,370 shares of the insurance provider’s stock worth $2,001,000 after purchasing an additional 170 shares during the period. DGS Capital Management LLC boosted its holdings in shares of Humana by 7.9% during the fourth quarter. DGS Capital Management LLC now owns 681 shares of the insurance provider’s stock worth $312,000 after purchasing an additional 50 shares during the last quarter. SVB Wealth LLC boosted its holdings in shares of Humana by 10.4% during the fourth quarter. SVB Wealth LLC now owns 1,475 shares of the insurance provider’s stock worth $675,000 after purchasing an additional 139 shares during the last quarter. Emfo LLC acquired a new stake in shares of Humana during the fourth quarter worth $687,000. Finally, Mackenzie Financial Corp boosted its holdings in shares of Humana by 75.7% during the fourth quarter. Mackenzie Financial Corp now owns 121,746 shares of the insurance provider’s stock worth $55,737,000 after purchasing an additional 52,469 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Insider Transactions at Humana
In other Humana news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.32% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on Humana
Humana Trading Up 1.9 %
NYSE:HUM opened at $323.46 on Thursday. The business’s 50-day moving average is $344.41 and its two-hundred day moving average is $425.71. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. Humana Inc. has a 12 month low of $299.23 and a 12 month high of $541.21. The firm has a market capitalization of $39.03 billion, a PE ratio of 16.32, a price-to-earnings-growth ratio of 1.86 and a beta of 0.45.
Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $26.46 billion during the quarter, compared to analysts’ expectations of $25.47 billion. During the same period last year, the business earned $1.62 earnings per share. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year. Research analysts predict that Humana Inc. will post 16.06 earnings per share for the current fiscal year.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. Humana’s payout ratio is 17.86%.
Humana Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- Basic Materials Stocks Investing
- Can Netflix Stock Continue Into All-Time Highs After Earnings?
- How to buy stock: A step-by-step guide for beginners
- Planet Labs Soars Fueled by AI Data Demand
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- These are the Top 4 Stocks for Buybacks in 2024
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.